Stage IV EGFR Mutated NSCL With Brain Metastases Recruiting Phase 3 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0084654 (Stage IV EGFR Mutated NSCL With Brain Metastases)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02882984Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)Treatment